BRAF and metastatic melanoma: Using a threshold of $33,357 per QALY, dabrafenib in combination with trametinib is a very cost-effective treatment option compared with vemurafenib for previously untreated patients with BRAF V600 mutation-positive unresectable or metastatic melanoma in China.